<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;B06A&quot;,&quot;href&quot;:&quot;atc/B06A.md&quot;},{&quot;label&quot;:&quot;chymotrypsin&quot;}]"></div>

# chymotrypsin

- **generic name:** chymotrypsin
- **ATC codes:** `B06AA04`, `S01KX01`
- **DrugBank:** [DB09375](https://go.drugbank.com/drugs/DB09375) · **PubChem:** not captured
- **groups:** approved, investigational, vet_approved, withdrawn

## About

Chymotrypsin is a protein-digesting enzyme used as a surgical aid in eye procedures and as an enzyme preparation affecting blood-related conditions. It is an approved medicine, also approved for veterinary use, though some products have been withdrawn.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q383836](https://www.wikidata.org/wiki/Q383836) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-06 01:18 | 8:54 | 0/0/0 | 0/0/0 | 0/0/0 | 356,166/7,180 | ollama / qwen3.8:27b-mtp-q8_0 | 20 | 7/53 | 20/0 | 0 |

## popPK records

_not available_

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 661 matched, 129 returned
- **screened:** 0  ·  **relevant:** 0
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_11 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Esimbekova_2017.pdf` | Esimbekova EN et al., Inhibition effect of food preservatives…, Food chemistry (2017) | pd | 5 | [10.1016/j.foodchem.2017.05.059](https://doi.org/10.1016/j.foodchem.2017.05.059) | [28554639](https://www.ncbi.nlm.nih.gov/pubmed/28554639) | metadata signals extractable PD data (EC50) |
| `Ming_2026.pdf` | Ming C et al., Development of a SMEDDS for oral delive…, Journal of pharmaceutical s… (2026) | pd | 5 | [10.1016/j.xphs.2026.104356](https://doi.org/10.1016/j.xphs.2026.104356) | [42250802](https://www.ncbi.nlm.nih.gov/pubmed/42250802) | metadata signals extractable PD data (PK/PD) |
| `Ryan_2011.pdf` | Ryan SM et al., PK/PD modelling of comb-shaped PEGylate…, Journal of controlled relea… (2011) | pd | 5 | [10.1016/j.jconrel.2010.10.004](https://doi.org/10.1016/j.jconrel.2010.10.004) | [20946924](https://www.ncbi.nlm.nih.gov/pubmed/20946924) | metadata signals extractable PD data (PK/PD) |
| `Fang_2015.pdf` | Fang EF et al., A trypsin inhibitor from rambutan seeds…, Applied biochemistry and bi… (2015) | pd | 4 | [10.1007/s12010-015-1550-1](https://doi.org/10.1007/s12010-015-1550-1) | [25820360](https://www.ncbi.nlm.nih.gov/pubmed/25820360) | metadata signals extractable PD data (IC50) |
| `Herbert_1992.pdf` | Herbert JM et al., Biochemical and pharmacological activit…, The Journal of pharmacology… (1992) | pd | 4 | not captured | [1738126](https://www.ncbi.nlm.nih.gov/pubmed/1738126) | metadata signals extractable PD data (IC50) |
| `Hiwada_1990.pdf` | Hiwada K et al., Effect of SQ29,852, a new angiotensin c…, General pharmacology (1990) | pd | 4 | [10.1016/0306-3623(90)90714-w](https://doi.org/10.1016/0306-3623(90)90714-w) | [2165961](https://www.ncbi.nlm.nih.gov/pubmed/2165961) | metadata signals extractable PD data (IC50) |
| `Kawabata_1991.pdf` | Kawabata K et al., ONO-5046, a novel inhibitor of human ne…, Biochemical and biophysical… (1991) | pd | 4 | [10.1016/0006-291x(91)91862-7](https://doi.org/10.1016/0006-291x(91)91862-7) | [2049103](https://www.ncbi.nlm.nih.gov/pubmed/2049103) | metadata signals extractable PD data (IC50) |
| `Li_2024.pdf` | Li J et al., A novel ACE inhibitory peptide from Dou…, Food chemistry (2024) | pd | 4 | [10.1016/j.foodchem.2024.140734](https://doi.org/10.1016/j.foodchem.2024.140734) | [39106751](https://www.ncbi.nlm.nih.gov/pubmed/39106751) | metadata signals extractable PD data (IC50) |
| `Moriyama_1983.pdf` | Moriyama A et al., Porcine liver succinyltrialanine p-nitr…, Journal of biochemistry (1983) | pd | 4 | [10.1093/oxfordjournals.jbchem.a134485](https://doi.org/10.1093/oxfordjournals.jbchem.a134485) | [6361013](https://www.ncbi.nlm.nih.gov/pubmed/6361013) | metadata signals extractable PD data (IC50) |
| `Rauf_2017.pdf` | Rauf A et al., Bioassay-guided isolation of novel and…, Chinese journal of natural… (2017) | pd | 4 | [10.1016/S1875-5364(18)30021-9](https://doi.org/10.1016/S1875-5364(18)30021-9) | [29329614](https://www.ncbi.nlm.nih.gov/pubmed/29329614) | metadata signals extractable PD data (IC50) |
| `He_2026.pdf` | He Q et al., A Phase I Single and Multiple Ascending…, Clinical therapeutics (2026) | pgx | 7 | [10.1016/j.clinthera.2026.03.017](https://doi.org/10.1016/j.clinthera.2026.03.017) | [41916795](https://www.ncbi.nlm.nih.gov/pubmed/41916795) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |

<sub>queue written 2026-10-06T01:13:26.279576+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Aggarwal_2023 | irrelevant | 0 | 0 | The paper is a mass spectrometry proteomics report identifying plant proteins (e.g., ribulose bisphosphate carboxylase) and contains no pharmacokinetic data for chymotrypsin. |
| PD | Aggarwal_2023 | not_relevant | 0 | 0 | The text is a mass spectrometry peptide summary report for plant proteins and contains no pharmacodynamic or exposure-response data for chymotrypsin. |
| popPK | Alberdi_1998 | irrelevant | 0 | 0 | The paper studies the binding of PEDF to glycosaminoglycans and uses chymotrypsin only as a proteolytic enzyme for limited proteolysis, not as a subject drug for pharmacokinetic analysis. |
| PD | Alberdi_1998 | not_relevant | 0 | 0 | The paper reports a binding affinity (EC50) for PEDF to heparan sulfate, not a pharmacodynamic or exposure-response relationship for chymotrypsin. |
| popPK | Algov_2026 | irrelevant | 0 | 0 | The paper describes a protease activity mapping platform for tumor detection and does not report pharmacokinetic parameters for chymotrypsin. |
| PD | Algov_2026 | not_relevant | 0 | 0 | The paper describes a protease substrate discovery platform (PSurf) and biosensor development, focusing on enzyme kinetics and tissue specificity, but does not report pharmacodynamic (exposure-response) parameters for the drug chymotrypsin. |
| popPK | Alves_2022 | irrelevant | 0 | 0 | The paper is a mechanistic study on marine bromoditerpenes as proteasome inhibitors, where chymotrypsin is only mentioned as a catalytic site for molecular docking, not as a subject drug for PK analysis. |
| PD | Alves_2022 | not_relevant | 0 | 0 | The paper studies bromoditerpenes as proteasome inhibitors and does not report any pharmacodynamic or exposure-response data for chymotrypsin. |
| popPK | Amer_2025 | irrelevant | 0 | 0 | The paper is a review on peptide delivery technologies and does not report pharmacokinetic parameters for chymotrypsin. |
| PD | Amer_2025 | not_relevant | 0 | 0 | The paper is a review on peptide delivery technologies and does not report any pharmacodynamic or exposure-response data for chymotrypsin. |
| popPK | Bao_2023 | irrelevant | 0 | 0 | The paper focuses on the design of SARS-CoV-2 3CL protease inhibitors, not the pharmacokinetics of the drug chymotrypsin. |
| PD | Bao_2023 | not_relevant | 0 | 0 | The paper reports an IC50 for a novel isatin derivative (5g) against SARS-CoV-2 3CLpro, not for the drug chymotrypsin, and does not provide a PD model or exposure-response relationship for chymotrypsin. |
| PGx | Baroni_2015 | not_relevant | 0 | 0 | The paper investigates the structure-function relationship of a Factor X mutation, not the pharmacokinetics or pharmacodynamics of the drug chymotrypsin. |
| popPK | Billings_1990 | irrelevant | 0 | 0 | The study investigates the anticarcinogenic effects of chymostatin (a chymotrypsin inhibitor) and Bowman-Birk inhibitor, not the pharmacokinetics of chymotrypsin itself. |
| PD | Billings_1990 | not_relevant | 3 | 2 | The paper reports a qualitative dose-response for a soybean extract (BBI) and a qualitative effect for chymostatin, but does not provide numeric PD parameters (e.g., EC50, Emax) or a quantitative concentration-effect curve for chymotrypsin. |
| popPK | Bognanni_2025 | irrelevant | 0 | 0 | The paper studies a suxibuzone-cyclodextrin conjugate's effect on proteasome activity, where "chymotrypsin-like" refers to a proteasome catalytic site, not the drug chymotrypsin. |
| popPK | Bohg_2026 | irrelevant | 0 | 0 | The paper is a mechanistic study on rhomboid protease inhibitors where chymotrypsin is used only as a negative control/comparator enzyme, not as the subject drug for pharmacokinetic analysis. |
| PD | Bohg_2026 | not_relevant | 0 | 0 | The paper focuses on the discovery and mechanistic characterization of inhibitors for the rhomboid protease GlpG; chymotrypsin is used only as a negative control for selectivity screening, and no pharmacodynamic or exposure-response analysis is performed for it. |
| popPK | Borovsky_1993 | irrelevant | 0 | 0 | The paper studies a peptide hormone (TMOF) that inhibits chymotrypsin-like enzyme biosynthesis in mosquitoes, rather than reporting pharmacokinetic parameters for chymotrypsin as a drug. |
| popPK | Bravo_2022 | irrelevant | 0 | 0 | The paper is a food science study on bioactive peptides from pigeon pea, using chymotrypsin only as a digestive enzyme for in-vitro hydrolysis, not as a subject drug for pharmacokinetic analysis. |
| PD | Bravo_2022 | not_relevant | 0 | 0 | The paper studies bioactive peptides from pigeon pea; chymotrypsin is used only as a proteolytic enzyme for digestion, not as a drug subject to pharmacodynamic analysis. |
| PGx | Brennan_1984 | not_relevant | 0 | 0 | The paper discusses proalbumin cleavage by chymotrypsin in the context of a proteinase inhibitor variant, but does not report pharmacokinetic or pharmacodynamic parameters of chymotrypsin itself. |
| popPK | Brown_2020 | irrelevant | 0 | 0 | The paper describes a high-throughput screening assay for SARS-CoV-2 protease inhibitors using a FRET biosensor, not a pharmacokinetic study of the drug chymotrypsin. |
| popPK | Byler_2020 | irrelevant | 0 | 0 | The paper is a computational study on SARS-CoV-2 inhibitors and does not involve chymotrypsin or pharmacokinetic parameters. |
| PD | Byler_2020 | not_relevant | 0 | 0 | The paper describes in silico virtual screening of natural products against SARS-CoV-2 proteins and does not involve chymotrypsin or report any pharmacodynamic or exposure-response data. |
| popPK | Castro_2006 | irrelevant | 0 | 0 | The paper studies the interaction between ecotin and thrombin, mentioning chymotrypsin only as a comparator enzyme inhibited by ecotin, with no pharmacokinetic data. |
| PD | Castro_2006 | not_relevant | 0 | 0 | The paper studies the interaction between ecotin and thrombin, not the pharmacodynamics of chymotrypsin. |
| popPK | Chhetri_2021 | irrelevant | 0 | 0 | The paper is a computational study of azo imidazole derivatives against SARS-CoV-2 protease and does not involve chymotrypsin or its pharmacokinetics. |
| PD | Chhetri_2021 | not_relevant | 0 | 0 | The paper is a computational study on azo imidazole derivatives against SARS-CoV-2 Mpro and does not involve chymotrypsin or report any pharmacodynamic exposure-response or dose-response relationships. |
| popPK | Chiang_1996 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of timolol, using chymotrypsin only as an agent to induce glaucoma in the animal model. |
| popPK | Chiou_2021 | irrelevant | 0 | 0 | The paper investigates the antiviral and anti-inflammatory properties of the flavonoid ugonin J against SARS-CoV-2, and "chymotrypsin" is only mentioned as part of the name of the viral protease (3-chymotrypsin-like protein), not as the subject drug for pharmacokinetic analysis. |
| popPK | Chorążewska_2026 | irrelevant | 0 | 0 | The paper describes the development and cellular uptake of a protein-drug conjugate (TriFHS-MMAE) targeting HSPGs, not the pharmacokinetics of chymotrypsin. |
| popPK | Concha_2004 | irrelevant | 0 | 0 | The study focuses on the immunological function of apolipoproteins in carp, using chymotrypsin only as a reagent for in vitro proteolysis, not as the subject of pharmacokinetic analysis. |
| PD | Concha_2004 | not_relevant | 0 | 0 | The paper studies apolipoproteins in fish; chymotrypsin is only used as a reagent for limited proteolysis, and no pharmacodynamic or exposure-response relationship for chymotrypsin is reported. |
| popPK | Dampalla_2023 | irrelevant | 0 | 0 | The paper describes antiviral inhibitors for SARS-CoV-2 and MERS-CoV proteases and does not involve chymotrypsin or its pharmacokinetics. |
| PD | Dampalla_2023 | not_relevant | 0 | 0 | The paper reports IC50/EC50 values for SARS-CoV-2 and MERS-CoV 3CL protease inhibitors, not pharmacodynamic or exposure-response data for the drug chymotrypsin. |
| popPK | Dang_2012 | irrelevant | 0 | 0 | The paper studies the chymotrypsin-like activity of the proteasome (an enzyme) in the context of Alzheimer's disease, not the pharmacokinetics of the drug chymotrypsin. |
| PGx | Diniz_2018 | not_relevant | 0 | 0 | The paper studies the behavioral phenotype of Elastase-2 knockout mice and its effect on BDNF levels, not the pharmacokinetics or pharmacodynamics of the drug chymotrypsin. |
| PGx | Dose_2016 | not_relevant | 0 | 0 | The paper investigates the effect of APOE genotype on hepatic stress response and proteasome activity, not the pharmacokinetics or pharmacodynamics of the drug chymotrypsin. |
| popPK | Elekofehinti_2021 | irrelevant | 0 | 0 | The study focuses on computational screening for SARS-CoV-2 3CLpro inhibitors, not the pharmacokinetics of the drug chymotrypsin. |
| PD | Elekofehinti_2021 | not_relevant | 0 | 0 | The paper is a computational study (docking, QSAR, MD) identifying potential inhibitors; it does not report experimental pharmacodynamic data, exposure-response relationships, or numeric PD parameters for chymotrypsin or any other drug. |
| popPK | Elsbaey_2022 | irrelevant | 0 | 0 | The paper is a phytochemical and in silico study of natural compounds against SARS-CoV-2 3CLpro (a chymotrypsin-like protease), not a pharmacokinetic study of the drug chymotrypsin. |
| PD | Elsbaey_2022 | not_relevant | 0 | 0 | The paper reports in vitro IC50 values for plant compounds against SARS-CoV-2 3CLpro, not a pharmacodynamic (exposure-response) relationship for the drug chymotrypsin. |
| popPK | Ertelt_2024 | irrelevant | 0 | 0 | The paper focuses on computational protein design and post-translational modifications, containing no pharmacokinetic data for chymotrypsin. |
| PD | Ertelt_2024 | not_relevant | 0 | 0 | The paper focuses on machine learning and protein design for post-translational modifications and does not contain any pharmacodynamic or exposure-response data for chymotrypsin. |
| PGx | Erukainure_2021 | not_relevant | 0 | 0 | The paper investigates the effect of L-leucine on chymotrypsin activity in the context of oxidative injury, not the effect of a gene variant on chymotrypsin pharmacokinetics or pharmacodynamics. |
| popPK | Esimbekova_2017 | irrelevant | 0 | 0 | no_text gate: only 58 chars of text extracted (&lt; 400) |
| PD | Esimbekova_2017 | not_relevant | 0 | 0 | The paper discusses the inhibition of endoproteinases by food preservatives, not the pharmacodynamics of chymotrypsin as a drug. |
| popPK | Ettari_2019 | irrelevant | 0 | 0 | The paper investigates proteasome inhibitors in multiple myeloma cells and mentions "chymotrypsin-like" activity as a protease function, but does not study the pharmacokinetics of the drug chymotrypsin. |
| popPK | Fang_2015 | irrelevant | 0 | 0 | The paper describes a trypsin inhibitor from rambutan seeds and its in-vitro biological activities, with no pharmacokinetic data for chymotrypsin. |
| PD | Fang_2015 | not_relevant | 3 | 2 | The paper reports an IC50 for HIV-1 RT and qualitative dose-dependent tumor inhibition, but lacks a formal PK/PD model or detailed concentration-effect curve analysis for chymotrypsin inhibition specifically. |
| popPK | Ge_2017 | irrelevant | 0 | 0 | The paper focuses on the design and biological evaluation of proteasome inhibitors, not the pharmacokinetics of chymotrypsin. |
| popPK | Ghaffari_2016 | irrelevant | 0 | 0 | The paper investigates the in-vitro enzyme inhibition of chymotrypsin by plant extracts, not the pharmacokinetics of chymotrypsin as a drug. |
| PD | Ghaffari_2016 | not_relevant | 3 | 2 | The paper reports crude plant extract inhibition with IC50 values reported as "&gt;500 μmol" (non-numeric upper bounds) and does not provide a dose-response curve or specific PD parameters for the drug chymotrypsin itself. |
| popPK | Ghosh_2008 | irrelevant | 0 | 0 | The paper describes the synthesis and antiviral efficacy of inhibitors for the SARS-CoV chymotrypsin-like protease (3CLpro), not the pharmacokinetics of the drug chymotrypsin. |
| PD | Ghosh_2008 | not_relevant | 0 | 0 | The paper focuses on the synthesis and in vitro antiviral/enzyme activity of SARS-CoV 3CLpro inhibitors, not on chymotrypsin pharmacodynamics or exposure-response relationships. |
| popPK | Ghosh_2021 | irrelevant | 0 | 0 | The paper studies inhibitors of the SARS-CoV-2 chymotrypsin-like protease (3CLpro) enzyme, not the pharmacokinetics of the drug chymotrypsin. |
| PD | Ghosh_2021 | not_relevant | 0 | 0 | The paper reports in vitro enzyme inhibition (IC50) and antiviral efficacy (EC50) for SARS-CoV-2 3CLpro inhibitors, but does not report any pharmacodynamic or exposure-response relationship for chymotrypsin. |
| popPK | Grosche_2026 | irrelevant | 0 | 0 | The paper studies the antiviral activity of a flavonoid against SARS-CoV-2, where chymotrypsin-like protease is a viral target, not a drug subject to PK analysis. |
| PD | Grosche_2026 | not_relevant | 0 | 0 | The paper reports antiviral activity (EC50/CC50) for a novel compound (LFA) against SARS-CoV-2, not pharmacodynamic parameters for the drug chymotrypsin. |
| popPK | Guedes_2023 | irrelevant | 0 | 0 | The paper is a study on proteasome inhibitors where "chymotrypsin-like" refers to an enzyme active site, not the drug chymotrypsin, and no PK parameters are reported. |
| PD | Guedes_2023 | not_relevant | 3 | 2 | The paper reports IC50 values for proteasome inhibition and cell viability, which are single-point potency metrics rather than a full exposure-response or dose-response curve with derived PD parameters (like Emax, EC50, or slope) for chymotrypsin specifically. |
| popPK | Guerciolini_1997 | irrelevant | 0 | 0 | The paper discusses the mechanism of action of orlistat and mentions chymotrypsin only as an enzyme not inhibited by the drug, providing no pharmacokinetic parameters for chymotrypsin. |
| PD | Guerciolini_1997 | not_relevant | 3 | 2 | The text describes the mode of action of orlistat and mentions it has no activity against chymotrypsin, but it does not report a PD relationship or numeric PD parameters for chymotrypsin itself. |
| popPK | Gupta_2019 | irrelevant | 0 | 0 | The paper describes the pharmacokinetics of ixazomib, a proteasome inhibitor, and only mentions chymotrypsin as the name of the proteolytic site (chymotrypsin-like) that ixazomib inhibits, not as the subject drug. |
| popPK | Hayat_2024 | irrelevant | 0 | 0 | The paper is an in silico study on Ebola virus protein inhibitors and does not involve chymotrypsin or pharmacokinetic parameters. |
| PD | Hayat_2024 | not_relevant | 0 | 0 | The paper is an in silico study on Ebola virus inhibitors and does not involve chymotrypsin or report any pharmacodynamic or exposure-response data. |
| PGx | He_2026 | not_relevant | 0 | 0 | The study evaluates the pharmacokinetics of SAL0133 (a chymotrypsin-like protease inhibitor) but does not report any pharmacogenomic effects or gene variant analyses. |
| popPK | Hejazi_2021 | irrelevant | 0 | 0 | The paper is an in silico study on phytoconstituents against SARS-CoV-2 and does not involve chymotrypsin or pharmacokinetics. |
| PD | Hejazi_2021 | not_relevant | 0 | 0 | The paper is an in silico molecular docking and dynamics study of phytoconstituents against SARS-CoV-2 protease; it does not involve chymotrypsin or report any pharmacodynamic (exposure-response) data. |
| popPK | Herbert_1992 | irrelevant | 0 | 0 | The study focuses on the pharmacological activity of the elastase inhibitor SR 26831, and chymotrypsin is only mentioned as a comparator enzyme that was not inhibited, with no PK parameters reported for chymotrypsin. |
| popPK | Hiwada_1990 | irrelevant | 0 | 0 | The paper is an in-vitro study of an ACE inhibitor (SQ29,852) where chymotrypsin is only mentioned as a negative control for enzyme specificity, with no pharmacokinetic parameters reported. |
| PD | Hiwada_1990 | not_relevant | 0 | 0 | The paper reports that the drug SQ29,852 has no inhibitory effect on chymotrypsin, and does not provide any exposure-response or dose-response data for chymotrypsin itself. |
| popPK | Hrvat_2020 | irrelevant | 0 | 0 | The paper is a review on chemical warfare nerve agent poisoning and does not contain pharmacokinetic data for chymotrypsin. |
| PD | Hrvat_2020 | not_relevant | 0 | 0 | The paper is a review of nerve agent poisoning mechanisms and treatments (atropine, oximes, bioscavengers) and does not report any pharmacodynamic or exposure-response data for chymotrypsin. |
| popPK | Ilyaskin_2026 | irrelevant | 0 | 0 | The paper investigates the structural and functional roles of GRIP domains in epithelial sodium channels (ENaC) and does not report pharmacokinetic parameters for chymotrypsin. |
| PD | Ilyaskin_2026 | not_relevant | 0 | 0 | The paper focuses on the structural and functional roles of GRIP domains in ENaC subunits using electrophysiology and simulations, and does not report any pharmacodynamic or exposure-response analysis for chymotrypsin. |
| popPK | Islam_2022 | irrelevant | 0 | 0 | The paper is a review on immune system rejuvenation and coronavirus infection, with no mention of chymotrypsin or pharmacokinetic parameters. |
| PD | Islam_2022 | not_relevant | 0 | 0 | The paper is a general review on immune system rejuvenation and does not contain any pharmacodynamic or exposure-response data for chymotrypsin. |
| PGx | Jan_2023 | not_relevant | 0 | 0 | The paper is a proteomic study of fish muscle proteins and does not investigate pharmacogenomic effects on the pharmacokinetics or pharmacodynamics of chymotrypsin as a drug. |
| popPK | Jiang_2023 | irrelevant | 0 | 0 | The paper focuses on the enzymatic inhibition of SARS-CoV-2 3CLpro (a protease) by isatin derivatives, not the pharmacokinetics of the drug chymotrypsin. |
| PD | Jiang_2023 | not_relevant | 0 | 0 | The paper reports in vitro enzymatic IC50 values for SARS-CoV-2 3CLpro inhibitors, which is a pharmacological potency assay, not a pharmacodynamic (exposure-response) or PK/PD analysis for chymotrypsin. |
| popPK | Jorda_2021 | irrelevant | 0 | 0 | The paper studies proteasome inhibitors targeting the chymotrypsin-like activity of the proteasome, not the pharmacokinetics of the drug chymotrypsin. |
| popPK | Karges_2023 | irrelevant | 0 | 0 | The paper describes the synthesis and in-vitro inhibition of SARS-CoV-2 main protease (3CLpro) by rhenium complexes, not the pharmacokinetics of the drug chymotrypsin. |
| popPK | Kawabata_1991 | irrelevant | 0 | 0 | The paper studies the inhibitor ONO-5046, and chymotrypsin is only mentioned as a non-target enzyme in an in-vitro inhibition assay, with no pharmacokinetic parameters reported. |
| PD | Kawabata_1991 | not_relevant | 0 | 0 | The paper reports that ONO-5046 did not inhibit chymotrypsin even at 100 microM, providing no dose-response curve or numeric PD parameters for chymotrypsin. |
| popPK | Kawall_2022 | irrelevant | 0 | 0 | The paper is an in-vitro study on phytochemical inhibition of SARS-CoV-2 PLpro and does not report pharmacokinetic parameters for chymotrypsin. |
| PD | Kawall_2022 | not_relevant | 0 | 0 | The paper investigates the inhibitory effects of phytochemicals on SARS-CoV-2 PLpro, not the pharmacodynamics of chymotrypsin. |
| popPK | Kern_2021 | irrelevant | 0 | 0 | The paper models viral kinetics for SARS-CoV-2 treatment with hydroxychloroquine, lopinavir/ritonavir, ivermectin, artemisinin, and nitazoxanide, and does not involve chymotrypsin. |
| PD | Kern_2021 | not_relevant | 0 | 0 | The paper models viral kinetics for hydroxychloroquine, lopinavir/ritonavir, ivermectin, artemisinin, and nitazoxanide, but does not mention or analyze chymotrypsin. |
| popPK | Kern_2021_2 | irrelevant | 0 | 0 | The paper models viral kinetics for SARS-CoV-2 treatment with hydroxychloroquine, lopinavir/ritonavir, ivermectin, artemisinin, and nitazoxanide, and does not involve chymotrypsin. |
| PD | Kern_2021_2 | not_relevant | 0 | 0 | The paper models SARS-CoV-2 viral kinetics for hydroxychloroquine, lopinavir/ritonavir, ivermectin, artemisinin, and nitazoxanide, but does not mention or model chymotrypsin. |
| popPK | Kisselev_2002 | irrelevant | 0 | 0 | The paper describes the enzymatic mechanism of the 20S proteasome (specifically chymotrypsin-like active sites) and does not report pharmacokinetic parameters for the drug chymotrypsin. |
| PD | Kisselev_2002 | not_relevant | 0 | 0 | The paper describes the allosteric mechanism of 20S proteasome activation by peptides, not the pharmacodynamics of the drug chymotrypsin. |
| popPK | Kobayashi_1985 | irrelevant | 0 | 0 | The provided evidence contains only metadata and software version information, with no pharmacokinetic data or text regarding chymotrypsin. |
| PD | Kobayashi_1985 | not_relevant | 0 | 0 | The provided text is metadata for the GROBID software and does not contain any scientific content regarding chymotrypsin or pharmacodynamics. |
| PGx | Kobielak_2014 | not_relevant | 0 | 0 | The paper studies protease-resistant variants of FGF1, not the pharmacogenomics of chymotrypsin. |
| popPK | Kumar_2024 | irrelevant | 0 | 0 | The paper is a computational study on phytochemical inhibitors of furin for COVID-19 and does not involve chymotrypsin or pharmacokinetic parameters. |
| PD | Kumar_2024 | not_relevant | 0 | 0 | The paper is a computational study (virtual screening, docking, MD simulations) of phytochemicals targeting furin protease and does not involve chymotrypsin or report any pharmacodynamic (exposure-response) data. |
| popPK | LaDuca_1986 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of platelet-collagen interaction where chymotrypsin is used only as a reagent to digest membrane glycoproteins, not as a subject drug for pharmacokinetic analysis. |
| PD | LaDuca_1986 | not_relevant | 0 | 0 | The paper investigates the interaction of ristocetin, vWF, and collagen on platelet aggregation; chymotrypsin is used only as a proteolytic tool to remove glycoproteins, not as a drug with a reported exposure-response or dose-response relationship. |
| PGx | Laffoon_2022 | not_relevant | 0 | 0 | The paper investigates plasma protein biomarkers for Alzheimer's disease and does not report pharmacokinetic or pharmacodynamic parameters of chymotrypsin. |
| popPK | Lam_2010 | irrelevant | 0 | 0 | The paper describes a chymotrypsin inhibitor (a protein from Acacia confusa) and its biological activities, not the pharmacokinetics of the drug chymotrypsin. |
| popPK | Larionova_1996 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of Bowman-Birk soybean protease inhibitor (BBI), not chymotrypsin, which is only mentioned as a target enzyme for inhibition. |
| PGx | Lechner_1995 | not_relevant | 0 | 0 | The paper investigates the effect of chymotrypsin digestion on hCG epitopes for diagnostic assay standardization, not the pharmacokinetics or pharmacodynamics of chymotrypsin as a drug. |
| popPK | Li_2019 | irrelevant | 0 | 0 | The paper studies copper complexes that inhibit proteasomal chymotrypsin-like activity in cancer cells, not the pharmacokinetics of the drug chymotrypsin. |
| popPK | Li_2024 | irrelevant | 0 | 0 | The study focuses on ACE inhibitory peptides from Douchi hydrolysate, using chymotrypsin only as a digestive enzyme for hydrolysis, not as the subject drug for pharmacokinetic analysis. |
| popPK | Lin_2023 | irrelevant | 0 | 0 | The study reports pharmacokinetic parameters for carfilzomib, not chymotrypsin. |
| PD | Lin_2023 | not_relevant | 0 | 0 | The paper reports a PK/PD model for carfilzomib, not chymotrypsin. |
| popPK | Mast_2021 | irrelevant | 0 | 0 | The paper focuses on nanobodies targeting SARS-CoV-2 and contains no pharmacokinetic data for chymotrypsin. |
| PD | Mast_2021 | not_relevant | 0 | 0 | The paper focuses on nanobodies against SARS-CoV-2 and does not report any pharmacodynamic or exposure-response data for chymotrypsin. |
| popPK | Medrano_2024 | irrelevant | 0 | 0 | The paper describes antiviral inhibitors of SARS-CoV-2 main protease and cathepsin L, with no mention of chymotrypsin pharmacokinetics. |
| PD | Medrano_2024 | not_relevant | 0 | 0 | The paper reports in vitro enzyme inhibition (Ki) and antiviral activity (EC50) for SARS-CoV-2 Mpro inhibitors, but does not contain any data, analysis, or mention of chymotrypsin. |
| popPK | Ming_2026 | irrelevant | 0 | 0 | no_text gate: only 139 chars of text extracted (&lt; 400) |
| PD | Ming_2026 | not_relevant | 0 | 0 | The paper focuses on difelikefalin acetate, not chymotrypsin, and does not report PD parameters for the specified drug. |
| popPK | Moravec_2009 | irrelevant | 0 | 0 | The paper describes in vitro assays for proteasome chymotrypsin-like activity, not the pharmacokinetics of the drug chymotrypsin. |
| popPK | Moriyama_1983 | irrelevant | 0 | 0 | The paper describes the purification and characterization of a porcine liver enzyme (post-proline cleaving enzyme) and uses chymotrypsin only as a negative control for substrate specificity, containing no pharmacokinetic data for chymotrypsin. |
| PD | Moriyama_1983 | not_relevant | 0 | 0 | The paper characterizes a purified enzyme (prolyl oligopeptidase) and reports IC50 values for its inhibitors, but does not report a pharmacodynamic exposure-response or dose-response relationship for the drug chymotrypsin. |
| PGx | Nieves_2010 | not_relevant | 0 | 0 | The paper studies a mutated receptor (u-PAR) and its interaction with chymotrypsin, but does not report pharmacogenomic effects on the PK/PD of chymotrypsin as a drug. |
| popPK | Noptana_2026 | irrelevant | 0 | 0 | The study uses chymotrypsin as an enzymatic reagent for hydrolysis, not as a subject drug for pharmacokinetic analysis. |
| PD | Noptana_2026 | not_relevant | 0 | 0 | The paper uses chymotrypsin as a proteolytic enzyme to generate peptides and reports antioxidant activity of the resulting hydrolysates, not a pharmacodynamic or exposure-response relationship for chymotrypsin itself. |
| popPK | Orlova_1987 | irrelevant | 0 | 0 | The paper investigates radiation inactivation mechanisms of alpha-chymotrypsin in vitro, not pharmacokinetic disposition parameters. |
| PD | Orlova_1987 | not_relevant | 0 | 0 | The paper discusses radiation inactivation (physical chemistry/radiobiology) of the enzyme, not pharmacodynamic drug exposure-response relationships. |
| PGx | Paliwal_2014 | not_relevant | 0 | 0 | The paper discusses genetic risk factors for tropical calcific pancreatitis, not the pharmacokinetics or pharmacodynamics of chymotrypsin as a drug. |
| popPK | Pandey_2025 | irrelevant | 0 | 0 | The paper investigates the antiviral mechanism of 9-aminominocycline against SARS-CoV-2 and does not report pharmacokinetic parameters for the drug chymotrypsin. |
| popPK | Papadopoulou_2025 | irrelevant | 0 | 0 | The paper is a review on marine bioactives for cosmetics and does not contain pharmacokinetic data for chymotrypsin. |
| PD | Papadopoulou_2025 | not_relevant | 0 | 0 | The paper is a review on marine by-products for cosmetics and does not contain any pharmacodynamic or exposure-response data for chymotrypsin. |
| popPK | Phan_2025 | irrelevant | 0 | 0 | The paper models viral dynamics of SARS-CoV-2 and the pharmacokinetics of nirmatrelvir/ritonavir, not the drug chymotrypsin. |
| popPK | Pierce_2018 | irrelevant | 0 | 0 | The paper studies proteasome inhibitors in cell lines and mentions chymotrypsin-like activity as a proteasome sub-catalytic site, not the pharmacokinetics of the drug chymotrypsin. |
| PD | Pierce_2018 | not_relevant | 0 | 0 | The paper reports pharmacological activity (EC50/Ki) for thiasyrbactins, not chymotrypsin, and does not provide a PD model or exposure-response relationship for chymotrypsin. |
| popPK | Quah_2019 | irrelevant | 0 | 0 | The paper is a study on the purification of cytotoxic peptides from a soft coral, where chymotrypsin is used only as a hydrolytic enzyme, not as the subject drug for pharmacokinetic analysis. |
| PD | Quah_2019 | not_relevant | 0 | 0 | The paper reports EC50 values for novel peptides isolated using chymotrypsin, but does not report a pharmacodynamic or exposure-response relationship for the drug chymotrypsin itself. |
| popPK | Rauf_2017 | irrelevant | 0 | 0 | The paper is a pharmacological study on enzyme inhibition (urease, chymotrypsin) and does not report pharmacokinetic parameters for chymotrypsin. |
| PD | Rauf_2017 | not_relevant | 0 | 0 | The paper reports in vitro enzyme inhibition (IC50) for urease and mentions chymotrypsin screening, but does not provide numeric PD parameters or exposure-response relationships for chymotrypsin. |
| popPK | Ren_2021 | irrelevant | 0 | 0 | The paper is a food science study on the antioxidant activity of rice protein hydrolysates, where chymotrypsin is used as a hydrolyzing enzyme rather than as a subject drug for pharmacokinetic analysis. |
| PD | Ren_2021 | not_relevant | 0 | 0 | The paper investigates the antioxidant activity of protein hydrolysates produced by chymotrypsin, not the pharmacodynamics of chymotrypsin itself; no exposure-response or dose-response relationship for the enzyme is reported. |
| popPK | Ren_2023 | irrelevant | 0 | 0 | The paper studies SARS-CoV-2 protease inhibitors and mentions chymotrypsin only as a negative control for selectivity, not as a subject of pharmacokinetic analysis. |
| PD | Ren_2023 | not_relevant | 0 | 0 | The paper reports IC50 values for SARS-CoV-2 proteases and mentions negligible effect on chymotrypsin, but does not provide a dose-response curve or numeric PD parameters for chymotrypsin. |
| popPK | Ryan_2011 | irrelevant | 0 | 0 | no_text gate: only 100 chars of text extracted (&lt; 400) |
| PD | Ryan_2011 | not_relevant | 0 | 0 | The paper focuses on PK/PD modelling of salmon calcitonin conjugates, not chymotrypsin. |
| popPK | Sagie_2025 | irrelevant | 0 | 0 | The paper focuses on immunology and T cell therapy mechanisms, containing no pharmacokinetic data for chymotrypsin. |
| PD | Sagie_2025 | not_relevant | 0 | 0 | The paper focuses on TCR-T cell therapy and chemotherapy synergy in cancer models; it does not contain any pharmacokinetic or pharmacodynamic data for chymotrypsin. |
| popPK | Sarkar_2021 | irrelevant | 0 | 0 | The paper is a computational study on SARS-CoV-2 inhibitors and does not involve chymotrypsin or pharmacokinetic parameters. |
| PD | Sarkar_2021 | not_relevant | 0 | 0 | The paper is a computational docking study of quinolines against SARS-CoV-2 proteins and does not contain any pharmacodynamic or exposure-response data for chymotrypsin. |
| popPK | Sarkar_2026 | irrelevant | 0 | 0 | The paper is a review of quercetin in COPD and does not contain any pharmacokinetic data for chymotrypsin. |
| PD | Sarkar_2026 | not_relevant | 0 | 0 | The paper is a review of quercetin in COPD and does not mention chymotrypsin or report any pharmacodynamic parameters. |
| popPK | Sawant_2026 | irrelevant | 0 | 0 | The paper studies the mechanism of action of proteasomal inhibitors (Bortezomib and Carfilzomib) on endothelial cells and does not involve chymotrypsin or its pharmacokinetics. |
| PD | Sawant_2026 | not_relevant | 0 | 0 | The paper studies Bortezomib and Carfilzomib, not chymotrypsin, and reports only qualitative or single-dose in vitro effects without a dose-response curve or PD parameters for the target drug. |
| popPK | Shi_2025 | irrelevant | 0 | 0 | The paper focuses on virtual screening for norovirus 3CL protease inhibitors and does not involve chymotrypsin or its pharmacokinetics. |
| PD | Shi_2025 | not_relevant | 0 | 0 | The paper focuses on virtual screening and in vitro enzyme/cell activity (EC50) for norovirus inhibitors, containing no pharmacokinetic data or exposure-response/PD modeling for chymotrypsin. |
| popPK | Shih_2022 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of Pentarlandir UPPTA (tannic acids), not chymotrypsin, which is only mentioned as a viral protease target (3CLpro). |
| popPK | Shimizu_2023 | irrelevant | 0 | 0 | The study evaluates the pharmacokinetics of ensitrelvir and its drug-drug interactions with CYP3A substrates (dexamethasone, prednisolone, midazolam), not the drug chymotrypsin. |
| popPK | Silva-Mendonça_2026 | irrelevant | 0 | 0 | The paper focuses on the discovery of inhibitors for the SARS-CoV-2 3-chymotrypsin-like protease (an enzyme), not the pharmacokinetics of the drug chymotrypsin. |
| PD | Silva-Mendonça_2026 | not_relevant | 0 | 0 | The paper reports in vitro IC50 values for enzyme inhibition (3CLpro) as part of a virtual screening study, but does not report pharmacokinetic data, exposure-response relationships, or pharmacodynamic models (e.g., Emax, EC50 in a PK/PD context) for the drug in a biological system. |
| PGx | Silva-Mendonça_2026 | not_relevant | 0 | 0 | The paper reports in silico discovery and in vitro inhibition of the SARS-CoV-2 3CLpro protease, not the pharmacokinetics or pharmacodynamics of the drug chymotrypsin. |
| popPK | Simeon_2021 | irrelevant | 0 | 0 | The study focuses on the protease stability of DARPins, using chymotrypsin only as a reagent for digestion assays, not as the subject of pharmacokinetic analysis. |
| PD | Simeon_2021 | not_relevant | 0 | 0 | The paper reports the effect of chymotrypsin on the stability of a DARPin (T10-2) and its subsequent anti-toxin potency, but does not report a pharmacodynamic exposure-response or dose-response relationship for chymotrypsin itself. |
| PGx | Singh_2021 | not_relevant | 0 | 0 | The paper discusses amentoflavone as a potential antiviral and its interaction with CYP enzymes, but does not report pharmacogenomic effects on the PK/PD of chymotrypsin. |
| PGx | Singh_2025 | not_relevant | 0 | 0 | The paper investigates the antiviral mechanism of a small molecule (TMD) against SARS-CoV-2 proteases and does not report any pharmacogenomic effects on the PK or PD of chymotrypsin. |
| popPK | Stratton_2017 | irrelevant | 0 | 0 | The paper is a mechanistic study on mercury-induced denaturation and aggregation of chymotrypsin, not a pharmacokinetic study, and contains no disposition parameters. |
| PD | Stratton_2017 | not_relevant | 3 | 2 | The paper reports biochemical inhibition and denaturation data (e.g., DEPC IC50) but does not provide a pharmacodynamic exposure-response model or numeric PD parameters for chymotrypsin itself. |
| popPK | Sureja_2022 | irrelevant | 0 | 0 | The paper is an in-silico study of lignan derivatives against SARS-CoV-2 and does not involve chymotrypsin or pharmacokinetic parameters. |
| PD | Sureja_2022 | not_relevant | 0 | 0 | The paper is an in-silico computational study on lignan derivatives for SARS CoV-2 and does not involve chymotrypsin or report any pharmacodynamic or exposure-response data. |
| popPK | Tan_2019 | irrelevant | 0 | 0 | The paper is a review of the pharmacokinetics of bortezomib, a proteasome inhibitor, and mentions chymotrypsin only as the target site of the drug's mechanism of action, not as the subject drug. |
| popPK | Thisted_2024 | irrelevant | 0 | 0 | The paper studies the pharmacokinetics of the antibody SNS-101, not chymotrypsin. |
| PD | Thisted_2024 | not_relevant | 0 | 0 | The paper focuses on the antibody SNS-101 (anti-VISTA), not chymotrypsin, and does not report any pharmacodynamic parameters for chymotrypsin. |
| PGx | Tian_2024 | not_relevant | 0 | 0 | The paper discusses the development of inhibitors for the viral enzyme 3-chymotrypsin-like protease (3CLpro), not the pharmacogenomics of the drug chymotrypsin. |
| PGx | Tremblay_2014 | not_relevant | 0 | 0 | The paper investigates the association of CTRC and SPINK1 gene variants with the risk of recurrent pancreatitis hospitalizations, not the pharmacokinetic or pharmacodynamic parameters of chymotrypsin as a drug. |
| popPK | Venkatraman_2023 | irrelevant | 0 | 0 | The paper describes a machine learning tool for molecular activity prediction and does not contain any pharmacokinetic data for chymotrypsin. |
| PD | Venkatraman_2023 | not_relevant | 0 | 0 | The paper describes a machine learning tool for predicting molecular activity from fingerprints and does not contain any pharmacodynamic data, exposure-response analysis, or specific information regarding chymotrypsin. |
| PGx | Verdin_1988 | not_relevant | 0 | 0 | The paper studies viral clearance mechanisms and uses chymotrypsin as a reagent, but does not report pharmacogenomic effects on the PK/PD of chymotrypsin. |
| popPK | Wang_2024 | irrelevant | 0 | 0 | The paper focuses on the discovery of SARS-CoV-2 protease inhibitors using DNA-encoded libraries and does not report pharmacokinetic parameters for the drug chymotrypsin. |
| PD | Wang_2024 | not_relevant | 0 | 0 | The paper reports in vitro enzyme inhibition (IC50) for SARS-CoV-2 proteases and polymerase, not pharmacodynamic (exposure-response) relationships for the drug chymotrypsin. |
| popPK | Wang_2025 | irrelevant | 0 | 0 | The study focuses on identifying inhibitors of the 3-chymotrypsin-like protease (3CLpro) enzyme, not on the pharmacokinetics of the drug chymotrypsin. |
| PGx | Ward_2025 | not_relevant | 0 | 0 | The paper is an in silico study identifying potential modifier genes for pain in cystic fibrosis and does not report pharmacokinetic or pharmacodynamic effects of chymotrypsin. |
| popPK | Wintroub_1986 | irrelevant | 0 | 0 | The paper characterizes a chymotrypsin-like enzyme (chymase) in mast cells using in-vitro kinetic assays (Km, pH, inhibition) and does not report pharmacokinetic disposition parameters (CL, V, t1/2) for the drug chymotrypsin. |
| PD | Wintroub_1986 | not_relevant | 3 | 2 | The paper reports an enzymatic Michaelis constant (Km) for a substrate, which is a kinetic parameter, but does not report a pharmacodynamic exposure-response or dose-response relationship for the drug chymotrypsin itself. |
| popPK | Wu_2022 | irrelevant | 0 | 0 | The paper focuses on the synthesis and biochemical evaluation of SARS-CoV-2 3CL protease inhibitors, not the pharmacokinetics of the drug chymotrypsin. |
| PD | Wu_2022 | not_relevant | 0 | 0 | The paper reports biochemical IC50 values for novel compounds against a viral enzyme, not a pharmacodynamic or exposure-response relationship for the drug chymotrypsin. |
| popPK | Xu_2025 | irrelevant | 0 | 0 | The study investigates peptides from fish for hyperuricemia inhibition and does not involve chymotrypsin pharmacokinetics. |
| PD | Xu_2025 | not_relevant | 0 | 0 | The paper investigates peptides from Trachurus japonicus, not chymotrypsin, and focuses on in silico docking and in vitro enzyme inhibition without reporting specific PD parameters for chymotrypsin. |
| popPK | Xue_2024 | irrelevant | 0 | 0 | The paper focuses on the development of inhibitors for the SARS-CoV-2 3-chymotrypsin-like protease enzyme, not the pharmacokinetics of the drug chymotrypsin. |
| PD | Xue_2024 | not_relevant | 3 | 2 | The paper reports an in vitro IC50 for a specific compound against an enzyme target, which is a pharmacodynamic potency metric, but it does not report an exposure-response or dose-response relationship for the drug in a biological system (e.g., plasma concentration vs. effect) or a PK/PD model. |
| popPK | Yakoby_2004 | irrelevant | 0 | 0 | The paper describes an in-vitro colorimetric method for measuring enzyme inhibition (IC50) and is not a pharmacokinetic study reporting disposition parameters for chymotrypsin. |
| popPK | Yang_2011 | irrelevant | 0 | 0 | The study investigates the pharmacological effects of schisandrin on rat colon contraction, using chymotrypsin only as a negative control agent, and contains no pharmacokinetic data for chymotrypsin. |
| PD | Yang_2011 | not_relevant | 0 | 0 | The paper studies the pharmacodynamics of schisandrin, not chymotrypsin; chymotrypsin is only mentioned as a negative control that did not affect the response. |
| popPK | Yao_2025 | irrelevant | 0 | 0 | The paper focuses on the pharmacokinetics of simnotrelvir, not chymotrypsin. |
| PD | Yao_2025 | not_relevant | 0 | 0 | The paper reports pharmacokinetic and exposure-response analyses for simnotrelvir, not chymotrypsin. |
| popPK | Yegneswaran_2004 | irrelevant | 0 | 0 | The paper is a mechanistic study on prothrombin and factor Va binding, where chymotrypsin is only mentioned as a homologous sequence reference, not as a subject of pharmacokinetic analysis. |
| PD | Yegneswaran_2004 | not_relevant | 0 | 0 | The paper studies a synthetic prothrombin peptide (PT473-487) and its interaction with Factor Va, not the drug chymotrypsin; the mention of chymotrypsin is only for sequence homology. |
| popPK | Yi_2022 | irrelevant | 0 | 0 | The study investigates the pharmacokinetics of schaftoside, not chymotrypsin. |
| popPK | Yu_2019 | irrelevant | 0 | 0 | The paper reports in-vitro proteasome inhibitory activity (IC50) for chymotrypsin-like activity, not pharmacokinetic disposition parameters for the drug chymotrypsin. |
| PD | Yu_2019 | not_relevant | 3 | 2 | The paper reports an in vitro IC50 for chymotrypsin-like activity, which is a pharmacodynamic parameter, but it is a single-point potency value from a biochemical assay, not an exposure-response or dose-response relationship analysis (e.g., Emax model, PK/PD fit) for the drug in a biological system. |
| popPK | Zapata-Cardona_2022 | irrelevant | 0 | 0 | The paper studies the antiviral activity of atorvastatin against SARS-CoV-2 and does not report pharmacokinetic parameters for chymotrypsin. |
| PGx | Zarnowski_2007 | not_relevant | 0 | 0 | The paper studies the production of chymotrypsin-like proteases by a fungus, not the pharmacokinetics or pharmacodynamics of chymotrypsin as a drug in humans. |
| popPK | Zhang_2016 | irrelevant | 0 | 0 | The paper focuses on the synthesis and biological evaluation of proteasome inhibitors, using chymotrypsin-like activity as a mechanistic assay rather than studying the pharmacokinetics of chymotrypsin itself. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
